Loading…
Zhejiang maker of vitamin A, vitamin E and antibiotic active ingredients, with a growing biologics investment arm.
Zhejiang maker of vitamin A, vitamin E and antibiotic active ingredients, with a growing biologics investment arm.
Sells vitamin A and E mostly into the animal-feed trade, where a handful of Chinese and European producers set global supply and prices swing with each plant's output and demand. Antibiotic ingredients are a second commodity-style line.
In one line: A Chinese vitamin/antibiotic API maker.
Moat: narrow (scale). Large-scale integrated vitamin API production is capital-intensive and slow for new entrants to match.
Headquarters: Shaoxing, Zhejiang, China · Employees: 5,417
Size Zhejiang Medicine (600216.SS) is a China Health Care company (Pharmaceuticals: Other) with a market value of $1.61B, the 1533rd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥11.14 on 6 Nov 2026.
Performance Over six months the shares fell 23.4%, against -2.5% for the median peer and -16.4% for the China market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue fell 5.9% over the last twelve months (peer median +11.8%); the operating margin is 7.0% (peer median 15.4%).
Valuation It trades at 11.3× forward earnings against a peer median of 18.6× (4th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -11 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.7 points above its cost of capital (6.4% WACC).
Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥8.43B | CN¥8.84B | CN¥9.33B | CN¥7.76B | CN¥8.08B |
| Revenue growth | — | -5% | +20% | -4% | — |
| Gross profit | CN¥3.20B | CN¥2.82B | CN¥3.72B | CN¥2.29B | CN¥2.53B |
| EBITDA | n/a | CN¥1.64B | CN¥2.02B | CN¥757M | CN¥1.14B |
| Net income | CN¥633M | CN¥873M | CN¥1.16B | CN¥430M | CN¥540M |
| Free cash flow | CN¥460M | CN¥1.44B | CN¥535M | -CN¥162M | -CN¥454M |
| Capital expenditure | CN¥532M | CN¥446M | CN¥689M | CN¥797M | CN¥976M |
| Total debt | CN¥993M | CN¥1.00B | CN¥807M | CN¥857M | CN¥899M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Zhejiang Medicine 600216.SS | $1.61B | -23% | -6% | 7% | 11.3× | -6.7% |
| Zhejiang NHU 002001.SZ | $12.3B | -23% | +11% | 33% | 9.9× | -7.8% |
| Xiamen Kingdomway 002626.SZ | $1.58B | +15% | -3% | 11% | 30.0× | n/a |
| DSM-Firmenich DSFIR.AS | $29.5B | +62% | -45% | 8% | 30.1× | 24.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600216.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -10.9% | +0.5% | 2nd lowest of 21 |
| 6-month return | -23.4% | -2.5% | 3rd lowest of 21 |
| Distance from 52-week high | -40.0% | -19.5% | 2nd lowest of 21 |
| Revenue growth (TTM) | -5.9% | +11.8% | 4th lowest of 21 |
| Operating margin | 7.0% | 15.4% | 5th lowest of 20 |
| Forward P/E | 11.3× | 18.6× | 4th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | -6.7% | 1.5% | 2nd least demanding of 17 |
| Growth delivered (Del g) | +3.9% | +10.4% | 4th lowest of 17 |
| Hurdle (Req g minus delivered) | -10.6 pp | -8.4 pp | 8th least demanding of 17 |
| ROIC minus cost of capital | +2.7 pp | +2.7 pp | 10th lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang Medicine 600216.SS | China | $1.61B | -23% | -6% | 7% | 11.3× | -6.7% | +3.9% |
| Tibet Cheezheng Tibetan Medicine 002287.SZ | China | $1.66B | -15% | -7% | 28% | n/a | -1.1% | +10.4% |
| Bora Pharmaceuticals 6472.TW | Taiwan | $1.55B | -2% | -6% | 15% | 14.2× | 4.5% | +60.2% |
| Guilin Sanjin Pharmaceutical 002275.SZ | China | $1.53B | +27% | -3% | 24% | 18.6× | -2.2% | +5.5% |
| Sudeep Pharma SUDEEPPHRM.NS | India | $1.41B | +75% | +27% | 33% | 67.7× | n/a | n/a |
| Porton Pharma Solutions 300363.SZ | China | $1.92B | +14% | +6% | -2% | n/a | 5.3% | +10.4% |
| Jamieson Wellness JWEL.TO | Canada | $1.35B | +35% | +15% | 15% | 21.2× | 11.0% | +15.3% |
| Cronos CRON.TO | Canada | $1.34B | +45% | +36% | -2% | 15.6× | 2.1% | +26.7% |
| Pharma Mar PHM.MC | Spain | $1.30B | -33% | +32% | 19% | 37.7× | 11.4% | -3.9% |
| China Meheco 600056.SS | China | $2.00B | -14% | +2% | 3% | n/a | -0.8% | -2.1% |
| Health and Happiness (H&H) International 1112.HK | Hong Kong | $2.05B | +70% | +24% | 16% | 12.6× | -3.0% | +4.4% |
| BioGaia BIOG-B.ST | Sweden | $1.26B | -7% | +13% | 28% | 30.1× | 0.9% | +15.5% |
| Granules India GRANULES.NS | India | $2.10B | +8% | +22% | 17% | 24.9× | 23.5% | +10.6% |
| China Resources Jiangzhong Pharmaceutical 600750.SS | China | $2.19B | -3% | -10% | 24% | 15.7× | -2.5% | +11.6% |
| HBM 2142.HK | Hong Kong | $1.18B | -23% | +55% | 44% | 12.4× | 14.1% | +62.3% |
| Shandong Xinhua Pharmaceutical 0719.HK | Hong Kong | $1.09B | -11% | -1% | 4% | 6.8× | -2.0% | +7.1% |
| China Resources Double-Crane Pharmaceutical 600062.SS | China | $2.50B | -10% | -1% | 13% | 9.8× | -8.3% | +5.3% |
| Applied Nutrition APN.L | United Kingdom | $1.01B | +42% | +24% | n/a | 24.2× | n/a | n/a |
| New Journey Health Technology Group Co., Ltd.Class A 002219.SZ | China | $999M | -16% | -14% | 8% | 193.0× | n/a | n/a |
| By-health 300146.SZ | China | $2.61B | -1% | +10% | 11% | 25.0× | 5.1% | +0.6% |
| Sihuan Pharmaceutical 0460.HK | Hong Kong | $952M | -35% | +30% | 15% | 9.7× | n/a | n/a |